Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

August 7, 2006 | APPEARED IN VOLUME 84, ISSUE 32

Cambrex has announced that Gary L. Mossman, its chief operating officer and president of Cambrex Pharma, will retire at the end of the month after three-and-a-half years at the company. Steven M. Klosk, who heads the biopharma division, will assume responsibility for the pharma business.

Bayer and Nufarm have entered into a multiyear European supply and distribution agreement for the herbicide diflufenican and products containing it. The herbicide was discovered by Bayer.

SABIC Europe has signed a contract with German contractor Uhde for the construction of a $250 million bimodal high-density polyethylene plant in Gelsenkirchen, Germany. The 250,000-metric-ton-per-year plant will open in late 2008, replacing a smaller facility at the site.

Afton Chemical has completed the first part of a two-part expansion of capacity for detergents used in lubricant additives. When completed by early next year, the overall project will raise detergent capacity by 20%, Afton says.

GenTek has acquired Repauno Products, a Gibbstown, N.J., producer of sodium nitrite, for $4.5 million. GenTek's General Chemical unit already operates a sodium nitrite plant in Syracuse, N.Y.

Hercules and ICI's Uniqema unit have agreed to a multiyear extension of their synthetic lubricants manufacturing pact. To accommodate Uniqema, Hercules plans to expand synlube capacity by the second quarter of 2007.

Galapagos' BioFocus DPI division has entered a pact with AstraZeneca worth close to $1 million. BioFocus will provide medicinal chemistry services to AstraZeneca's respiratory and inflammatory drug discovery programs.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment